It has been reported that overexpressed miR-30d downregulates Galphai2 (GNAI2), tumor protein p53 (TP53), GalNAc transferase (GALNT7), and Caspase 3 (CASP3) expression by direct targeting in hepatocellular carcinoma (HCC), multiple myeloma, malignant melanoma, and ovarian and breast cancers [30-33]. Here, GALNT7 is linked to plasma cell myeloma.